Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2009 Jan 10;27(2):220-6. doi: 10.1200/JCO.2008.17.9952. Epub 2008 Dec 1.

2.

Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.

Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM.

Cancer. 2010 Sep 1;116(17):4168-77. doi: 10.1002/cncr.25296.

3.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.

4.

African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.

Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Davidson NE, Jacobs L, Lange J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V.

J Clin Oncol. 2009 Aug 1;27(22):e35-7; author reply e38-9. doi: 10.1200/JCO.2008.21.5509. Epub 2009 Jun 29. No abstract available.

5.

Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.

Wright JL, Reis IM, Zhao W, Panoff JE, Takita C, Sujoy V, Gomez CR, Jorda M, Franceschi D, Hurley J.

Breast. 2012 Jun;21(3):276-83. doi: 10.1016/j.breast.2011.11.003. Epub 2011 Dec 16.

PMID:
22178596
6.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
7.

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X.

Med Oncol. 2012 Jun;29(2):547-53. doi: 10.1007/s12032-011-9964-2. Epub 2011 Apr 29.

PMID:
21528408
8.
9.

Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population.

Zhang X, Li P, Ma W, Di W, Zhao S, Gao Q, Zhao Y, Yang M, Zhang Q.

Sci China Life Sci. 2013 Apr;56(4):335-40. doi: 10.1007/s11427-013-4435-y. Epub 2013 Mar 12.

PMID:
23483340
10.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471
11.

Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR.

J Clin Oncol. 2015 Dec 20;33(36):4267-76. doi: 10.1200/JCO.2015.63.7801. Epub 2015 Nov 23.

PMID:
26598753
12.

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2006 Mar 1;24(7):1037-44.

PMID:
16505422
13.

The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.

Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS, Landry JC.

Ann Surg Oncol. 2011 Oct;18(10):2858-65. doi: 10.1245/s10434-011-1669-4. Epub 2011 Mar 26.

PMID:
21442346
14.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
15.

Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy.

Asaga S, Kinoshita T, Hojo T, Suzuki J, Jimbo K, Tsuda H.

Clin Breast Cancer. 2013 Feb;13(1):40-6. doi: 10.1016/j.clbc.2012.09.013. Epub 2012 Oct 25.

PMID:
23103363
16.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
17.

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.

Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L.

BMC Cancer. 2013 May 4;13:225. doi: 10.1186/1471-2407-13-225.

18.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

19.

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.

Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V.

JAMA Oncol. 2016 Apr;2(4):508-16. doi: 10.1001/jamaoncol.2015.4935.

20.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347

Supplemental Content

Support Center